Aim immunotech announces release of the next ceo corner segment

Ocala, fla., april 11, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), today announced the next ceo corner segment has been published on the company's website. for the ceo corner segment, thomas equels, chief executive officer of aim immunotech, discussed the company's recent news release regarding top-line interim data indicating that combining ampligen (rintatolimod) with keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect that could be far more effective than pembrolizumab alone as a therapy for the disease.
AIM Ratings Summary
AIM Quant Ranking